Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 65

Results For "UST"

5796 News Found

Senores Pharma doubles profit as sales surge 62%
News | May 15, 2026

Senores Pharma doubles profit as sales surge 62%

Global specialty pipeline accelerates growth


Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook
News | May 14, 2026

Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook

Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros


Merck KGaA raises 2026 outlook as life science & AI chip boom power strong Q1 growth
News | May 14, 2026

Merck KGaA raises 2026 outlook as life science & AI chip boom power strong Q1 growth

The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion


AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX
interviews | May 13, 2026

AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX

We are building an AI-native operating system for pharma sales and distribution


CII elects R Mukundan as President for 2026-27, Suchitra K Ella named President-Designate
People | May 13, 2026

CII elects R Mukundan as President for 2026-27, Suchitra K Ella named President-Designate

Shashwat Goenka takes over as Vice President of industry body


Breakthrough wearable heart failure therapy enables earlier hospital discharge: UK trial
Clinical Trials | May 13, 2026

Breakthrough wearable heart failure therapy enables earlier hospital discharge: UK trial

Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care


Actio Biosciences launches Phase 1b/2 trial for ultra-rare pediatric epilepsy therapy
News | May 13, 2026

Actio Biosciences launches Phase 1b/2 trial for ultra-rare pediatric epilepsy therapy

The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process